BD to Invest $1.2 Billion Over Four Years in Pre-Fillable Syringe Manufacturing Capacity

December 2, 2020
Pharmaceutical Technology Editors

The investment will expand and upgrade manufacturing capacity and technology for pre-fillable syringes and will also includes a new manufacturing facility in Europe.

Becton, Dickinson and Company (BD), a global medical technology company, announced on Dec. 2, 2020 that it plans to invest approximately $1.2 billion over a four-year period to expand pre-fillable syringe (PFS) capacity. In addition to expanding PFS manufacturing capacity and upgrading PFS manufacturing technology, the investment will also be used to expand advanced drug delivery systems (ADDS) across the company’s six global manufacturing locations in Columbus, Nebraska in the United States; Cuautitlán, Mexico; Fukushima, Japan; Le Pont-de-Claix, France; Swindon, United Kingdom; and Tatabánya, Hungary.

The investment will also include the addition of a new manufacturing facility in Europe, which is expected to be operational by the end of 2023. In addition, the investment will fund capacity expansion, new product innovations, manufacturing technology enhancements, and business continuity improvements across BD’s existing network. The BD network is designed to maximize supply and reduce risks for pharmaceutical companies that rely on ready-to-fill syringes for injectable drugs—including complex biologics, vaccines, and small molecules.

“BD invented the ready-to-fill, pre-fillable syringe technology, and today's announcement demonstrates our continued commitment to better serve our customers," said Eric Borin, worldwide president of BD Pharmaceutical Systems, in a company press release. "Since 2018, BD has added 350 million units of manufacturing capacity for glass barrel pre-fillable syringes, and this new commitment will invest in additional upgrades at all of our Pharmaceutical Systems manufacturing facilities and across multiple product categories. In addition, this investment positions BD to have the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines."

Source: Becton, Dickinson and Company